Within the dapagliflozin groups , dose-related reductions in @-h glucose , glycemic variability , and insulin dose were suggested , which provide hope that SGLT@ inhibition may prove in larger randomized controlled trials to be efficacious in reducing hyperglycemia in type @ diabetes .